Polytrap Pharma Private Limited

Polytrap Pharma Private Limited - chemicals and materials in Indore, Madhya Pradesh, India. FY 2026 financials and compliance.
CIN U24290MP2021PTC056502 Incorporated 01 July 2021 ROC Gwalior HQ Indore, Madhya Pradesh, India
Active Private Limited Company chemicals and materials
Data last updated
Revenue · FY 2024
₹2.02 Cr
▲ 61.00% YoY
EBITDA · FY 2024
*****
▲ 189.00% YoY
Net profit · FY 2024
*****
▲ 159.00% YoY
Authorised capital
₹50 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Open charges
None
Secured borrowings
Company age
5 yrs
Est. 2021
Last financials
Mar 2025
Balance sheet date

About Polytrap Pharma Private Limited

Data last updated: 06 February 2026

Polytrap Pharma Private Limited is a private limited company based in Indore, Madhya Pradesh, India. It specialises in dyes and pigments, a part of the broader chemicals and materials sector. Incorporated on 01 July 2021, the company has been in operation for over 5 years.

Registered with ROC Gwalior under CIN U24290MP2021PTC056502.

Capital: an authorised share capital of ₹50 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Deepti Shrivastava and Jyoti Shrivastava.

Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: 122 Prikanko Colony N. No. 80793, Indore, Madhya Pradesh, India – 452009.

As per the financials filed for FY 2024, the company reported a revenue of ₹2.02 Cr, a growth of 61% compared to the previous year.

Company Details of Polytrap Pharma Private Limited
CIN U24290MP2021PTC056502
Registration Number 056502
Incorporation Date 01 July 2021
ROC Gwalior
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Key People
Deepti Shrivastava Director Jyoti Shrivastava Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    **************
  • Social Media
    **************
  • Registered Address
    122 Prikanko Colony N. No. 80793, Indore, Madhya Pradesh, India – 452009
  • Industry
    Chemicals and Materials, Dyes & Pigments, Colorants
Company report
Polytrap Pharma Private Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Polytrap Pharma Private Limited report

Financials, compliance, directors, charges, ownership and filings for Polytrap Pharma Private Limited in one report.

10-year financials Directors & ownership Charges & compliance

Business Activity of Polytrap Pharma Private Limited

Polytrap Pharma Private Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including other professional, scientific and technical activities.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
M Professional, Scientific and Technical M9 Other professional, scientific and technical activities *********

Auditor Details of Polytrap Pharma Private Limited

Polytrap Pharma Private Limited is audited by R.D. JOSHI & CO. for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
R.D. JOSHI & CO. blur-value blur-value blur-value

Board of Directors of Polytrap Pharma Private Limited

Polytrap Pharma Private Limited is currently managed by 2 directors, with 2 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Deepti Shrivastava Director 01 Jul 2021 5 Years 0 Months Current
Jyoti Shrivastava Director 19 Nov 2021 4 Years 7 Months Current
View all directors

Financials of Polytrap Pharma Private Limited FY 2025 filings available

Polytrap Pharma Private Limited reported revenue of ₹2.02 Cr (up 61% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue
₹2.02 Cr ▲ 61%
Profit
***** ▲ 159%
EBITDA
***** ▲ 189%
Metrics
*****
*****
*****
*****
*****
Revenue
Revenue from Operations
*****
*****
*****
*****
*****
Revenue Growth %
*****
*****
*****
*****
*****
Other Income
*****
*****
*****
*****
*****
Total Revenue
*****
*****
*****
*****
*****
Expenses
Total Expenses
*****
*****
*****
*****
*****
Raw Material Cost
*****
*****
*****
*****
*****
Change in Inventory FG
*****
*****
*****
*****
*****
Change in Inventory WIP
*****
*****
*****
*****
*****
Purchase of Traded Goods
*****
*****
*****
*****
*****
Employee Cost
*****
*****
*****
*****
*****
Managerial Remuneration
*****
*****
*****
*****
*****
Audit Fees
*****
*****
*****
*****
*****
Insurance
*****
*****
*****
*****
*****
Power & Fuel
*****
*****
*****
*****
*****
Interest
*****
*****
*****
*****
*****
Depreciation
*****
*****
*****
*****
*****
Other Expenses
*****
*****
*****
*****
*****
Profitability
EBITDA (Operating Profit)
*****
*****
*****
*****
*****
Operating Margin %
*****
*****
*****
*****
*****
Exceptional Items
*****
*****
*****
*****
*****
Extraordinary Items
*****
*****
*****
*****
*****
Profit Before Exceptional & Extraordinary Items
*****
*****
*****
*****
*****
Profit Before Tax
*****
*****
*****
*****
*****
Tax & Net Profit
Tax Expense
*****
*****
*****
*****
*****
Current Tax
*****
*****
*****
*****
*****
Deferred Tax
*****
*****
*****
*****
*****
Profit from Discontinued Operations
*****
*****
*****
*****
*****
Tax on Discontinued Operations
*****
*****
*****
*****
*****
Profit
*****
*****
*****
*****
*****
Net Margin %
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Shareholders' Funds
Total Shareholders' Funds
*****
*****
*****
*****
*****
Equity Capital
*****
*****
*****
*****
*****
Reserves & Surplus
*****
*****
*****
*****
*****
Money Against Warrants
*****
*****
*****
*****
*****
Other Equity
*****
*****
*****
*****
*****
Non-Current Liabilities
Total Non-Current Liabilities
*****
*****
*****
*****
*****
Long-Term Borrowings
*****
*****
*****
*****
*****
Deferred Tax Liabilities
*****
*****
*****
*****
*****
Other Non-Current Liabilities
*****
*****
*****
*****
*****
Long-Term Provisions
*****
*****
*****
*****
*****
Current Liabilities
Total Current Liabilities
*****
*****
*****
*****
*****
Short-Term Borrowings
*****
*****
*****
*****
*****
Trade Payables
*****
*****
*****
*****
*****
Other Current Liabilities
*****
*****
*****
*****
*****
Short-Term Provisions
*****
*****
*****
*****
*****
Total Equity & Liabilities
*****
*****
*****
*****
*****
Non-Current Assets
Non-Current Assets
*****
*****
*****
*****
*****
Tangible Assets
*****
*****
*****
*****
*****
Intangible Assets
*****
*****
*****
*****
*****
Capital WIP
*****
*****
*****
*****
*****
Intangibles Under Dev
*****
*****
*****
*****
*****
Investments
*****
*****
*****
*****
*****
Deferred Tax Assets
*****
*****
*****
*****
*****
LT Loans & Advances
*****
*****
*****
*****
*****
Other Non-Current Assets
*****
*****
*****
*****
*****
Current Assets
Current Assets
*****
*****
*****
*****
*****
Current Investments
*****
*****
*****
*****
*****
Inventories
*****
*****
*****
*****
*****
Trade Receivables
*****
*****
*****
*****
*****
Cash & Bank Balance
*****
*****
*****
*****
*****
ST Loans & Advances
*****
*****
*****
*****
*****
Other Current Assets
*****
*****
*****
*****
*****
Total Assets
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Cash from Operating Activities (CFO)
Profit Before Tax
*****
*****
*****
*****
*****
Non-Cash Adjustments
*****
*****
*****
*****
*****
+ Interest Expense
*****
*****
*****
*****
*****
+ Depreciation
*****
*****
*****
*****
*****
+/- Unrealized Forex
*****
*****
*****
*****
*****
- Dividend Income
*****
*****
*****
*****
*****
- Interest Income
*****
*****
*****
*****
*****
+/- Other Non-Cash Items
*****
*****
*****
*****
*****
Changes in Working Capital
*****
*****
*****
*****
*****
+/- Inventory
*****
*****
*****
*****
*****
+/- Debtors
*****
*****
*****
*****
*****
+/- Creditors
*****
*****
*****
*****
*****
Reconciliation Adjustments
*****
*****
*****
*****
*****
Cash Generated from Operations
*****
*****
*****
*****
*****
Income Taxes Paid
*****
*****
*****
*****
*****
Net CFO (Cash from Operations)
*****
*****
*****
*****
*****
Cash from Investing Activities (CFI)
Acquisitions & Disposals
*****
*****
*****
*****
*****
Disposal of Subsidiaries
*****
*****
*****
*****
*****
Acquisition of Subsidiaries
*****
*****
*****
*****
*****
Capex
*****
*****
*****
*****
*****
Purchase of Fixed Assets
*****
*****
*****
*****
*****
Sale of Fixed Assets
*****
*****
*****
*****
*****
Other Investing Cash Flows
*****
*****
*****
*****
*****
Net CFI (Cash from Investing)
*****
*****
*****
*****
*****
Cash from Financing Activities (CFF)
Equity Issuance
*****
*****
*****
*****
*****
Debt Raised
*****
*****
*****
*****
*****
Debt Repaid
*****
*****
*****
*****
*****
Dividends Paid
*****
*****
*****
*****
*****
Interest Paid
*****
*****
*****
*****
*****
Net CFF (Cash from Financing)
*****
*****
*****
*****
*****
Net Cash Position
Net Change in Cash (Pre-Forex)
*****
*****
*****
*****
*****
Closing Cash & Equivalents
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Liquidity
Current Ratio
*****
*****
*****
*****
*****
Quick Ratio
*****
*****
*****
*****
*****
Cash Ratio
*****
*****
*****
*****
*****
Efficiency
Inventory Days
*****
*****
*****
*****
*****
Debtor Days
*****
*****
*****
*****
*****
Creditor Days
*****
*****
*****
*****
*****
Cash Conversion Cycle
*****
*****
*****
*****
*****
Asset Turnover
*****
*****
*****
*****
*****
Profitability
Net Profit Margin %
*****
*****
*****
*****
*****
Operating Margin %
*****
*****
*****
*****
*****
ROE %
*****
*****
*****
*****
*****
ROCE %
*****
*****
*****
*****
*****
Net Worth Margin %
*****
*****
*****
*****
*****
Growth
Revenue Growth %
*****
*****
*****
*****
*****
Leverage
Equity Multiplier
*****
*****
*****
*****
*****
Debt / EBITDA
*****
*****
*****
*****
*****
Solvency
D/E Ratio
*****
*****
*****
*****
*****
ICR
*****
*****
*****
*****
*****

Consolidated Statements

Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.

Unlock Complete Financial History (FY 2015 – Latest)
Standalone & Consolidated - Income Statement, Balance Sheet, Cash Flow, Financial Ratios and Growth Trends with 10+ years of line-item data.
10+ years of data Line-item breakdown Balance Sheet detail Cash Flow analysis 20+ ratios & metrics Downloadable PDF

Shareholding Pattern of Polytrap Pharma Private Limited

As of FY 2023, Polytrap Pharma Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.

2025
YEAR
38.19% Promoters
25.22% DII (Domestic Institutional)
10.28% FII (Foreign Institutional)
25.89% Public
2.42% Others
Shareholding Trend
Year 2025
Promoters 33.19%
DII 23.22%
FII 18.28%
Public 22.89%
Others 2.42%

Charges & Borrowings Polytrap Pharma Private Limited

Polytrap Pharma Private Limited does not have any charges (loans) registered with the Registrar of Companies.

Employees and EPFO Compliance at Polytrap Pharma Private Limited

Polytrap Pharma Private Limited has a workforce of 0 employees as of Mar 26, 2024.

Active EPFO establishments
1
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Polytrap Pharma Private Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Polytrap Pharma Private Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Polytrap Pharma Private Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Polytrap Pharma Private Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Polytrap Pharma Private Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Polytrap Pharma Private Limited

MSME Payment Delays by Polytrap Pharma Private Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Polytrap Pharma Private Limited

Subsidiaries & Group Companies of Polytrap Pharma Private Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Polytrap Pharma Private Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Polytrap Pharma Private Limited

MCA Filings & Documents of Polytrap Pharma Private Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Polytrap Pharma Private Limited

Activity
30 Sep 2025
Polytrap Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Polytrap Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Gwalior.
Directors
19 Nov 2021
Jyoti Shrivastava was appointed as a Director on 19 Nov 2021 & has been associated with this company since 4 years 7 months.
Directors
01 Jul 2021
Deepti Shrivastava was appointed as a Director on 01 Jul 2021 & has been associated with this company since 5 years 10 days.
Activity
01 Jul 2021
Polytrap Pharma Private Limited was registered on 01 Jul 2021 with Roc Gwalior & aged 5 years 10 days as per MCA records.

Frequently Asked Questions about Polytrap Pharma Private Limited

Polytrap Pharma Private Limited is an active private limited company in the chemicals and materials sector based in Indore, Madhya Pradesh, India. It was incorporated on 01 July 2021 (5+ years old) and is registered under CIN U24290MP2021PTC056502.

Polytrap Pharma Private Limited reported revenue of ₹2.02 Cr for FY 2024 (up 61.00% YoY).

The current directors of Polytrap Pharma Private Limited are:

The primary industry of Polytrap Pharma Private Limited is chemicals and materials. The company specifically operates in dyes and pigments. The company is currently active in this sector.

Polytrap Pharma Private Limited can be reached at the registered office: 122 Prikanko Colony N. No. 80793, Indore, Madhya Pradesh, India – 452009.

The authorised capital is ₹50 Lakh, and the paid-up capital is ₹1 Lakh.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available